A new study published in JAMA Ophthalmology found that the accuracy of survival prediction of patients with uveal melanoma may not be as reliable as previously thought.
“Adjuvant therapy trials may not be able to rely on predicted metastasis-free survival (MFS) to calculate efficacy with a high degree of confidence,” the authors of the study concluded.
In patients with class 2 tumor included in this cohort and in the literature, the observed metastasis-free survival rate was 62% at 3 years and 42% at 5 years, which were potentially better than the predicted rates.
The researchers found that patients with metastasis had larger tumors compared with nonmetastatic tumors and concluded that using tumor size in the prediction model may enhance its accuracy.
Reference
Singh AD, Binkley EM, Wrenn JM, et al. Predicted vs Observed Metastasis-Free Survival in Individuals With Uveal Melanoma. JAMA Ophthalmol. Published online July 21, 2022. doi:10.1001/jamaophthalmol.2022.2623
Related Content
